Company
Abbvie
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
4
510(k), De Novo and PMA
Device trials
35
As lead sponsor, any status
Adverse event reports
615
Received Nov 1, 2025 to Nov 20, 2026
Recall records
4
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
ABBV
NYSE · AbbVie Inc.
Public float
$325.1B
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$61.2B
Fiscal year ending Dec 31, 2025
Net income
$4.23B
Fiscal year ending Dec 31, 2025
R&D spending
$9.10B
Fiscal year ending Dec 31, 2025
Cash
$10.8B
As of Sep 30, 2026
Long-term debt
$72.2B
As of Sep 30, 2026
Shares outstanding
1767.6M
As of Oct 26, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2025 | – | – | $3.99B | – |
| 2024 | – | – | $17.0B | – |
| 2022 | – | – | $2.00B | – |
| 2021 | – | – | $1.00B | – |
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Apr 25, 2016 | Equity Issued in a merger or acquisition; not counted as money raised | $3.80B | $3.80B | 39 | Rule 506(b) | Form D ↗May 9, 2016 |
Company details
From the company's latest Form D.
- Legal name
- AbbVie Inc.
- Headquarters
- North Chicago, Illinois
- Incorporated
- Delaware in 2012
- Entity type
- Corporation
- Revenue range
- Over $100,000,000
- Industry filed under
- Pharmaceuticals
- SEC filer
- CIK 1551152 ↗
Executives, directors and promoters
As listed on the latest Form D.
17 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
K254126 · Decided Jan 16, 2026 · 28 days after receipt
Device type: Tissue Expander And Accessories (LCJ) · General & Plastic Surgery
- AbbVie NJ510(k)
K142792 · Decided Jan 14, 2015 · 110 days after receipt
Device type: Tubes, Gastrointestinal (And Accessories) (KNT) · GI, Urology & Nephrology
- AbbVie PEG510(k)
K142793 · Decided Jan 14, 2015 · 110 days after receipt
Device type: Tubes, Gastrointestinal (And Accessories) (KNT) · GI, Urology & Nephrology
1 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin SmoothnessPivotal-lookingRecruiting
NCT07880756 · 150 participants (planned) · Start Sep 16, 2026 · Primary completion Feb 2028
Device: NOA HYDRATION · For: Skin Quality
Sites: Beijing, China; Nanjing, China; Hangzhou, China · 4 sites in all
NCT06822738 · 130 participants (planned) · Start Feb 11, 2025 · Primary completion Nov 2028
Device: XEN63 Glaucoma Treatment System · For: Primary Open Angle Glaucoma
Sites: Glendale, Arizona; Culver City, California; Petaluma, California · 29 sites in all
NCT07794891 · 100 participants (planned) · Start Sep 9, 2026 · Primary completion Jun 2027
Device: SKINVIVE; VOLUX and 1 more · For: Jawline and Neck Appearance
Sites: Vancouver, Canada; Toronto, Canada
32 more trials with a free account
Reports received
615
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
59
9.6% of reports
Injury reports
550
89% of reports
Death reports
6
1.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 99 | 2 | 0 |
| Jan 24 | 0 | 57 | 1 | 0 |
| Feb 24 | 0 | 64 | 1 | 0 |
| Mar 24 | 0 | 69 | 1 | 0 |
| Apr 24 | 1 | 69 | 0 | 0 |
| May 24 | 0 | 63 | 1 | 0 |
| Jun 24 | 0 | 77 | 0 | 0 |
| Jul 24 | 0 | 56 | 0 | 0 |
| Aug 24 | 0 | 40 | 1 | 0 |
| Sep 24 | 0 | 46 | 0 | 0 |
| Oct 24 | 0 | 58 | 0 | 0 |
| Nov 24 | 0 | 48 | 0 | 0 |
| Dec 24 | 0 | 54 | 1 | 0 |
| Jan 25 | 0 | 45 | 2 | 0 |
| Feb 25 | 0 | 53 | 0 | 0 |
| Mar 25 | 0 | 61 | 0 | 0 |
| Apr 25 | 0 | 47 | 0 | 0 |
| May 25 | 1 | 47 | 1 | 0 |
| Jun 25 | 0 | 43 | 0 | 0 |
| Jul 25 | 0 | 45 | 1 | 0 |
| Aug 25 | 0 | 48 | 2 | 0 |
| Sep 25 | 0 | 42 | 0 | 0 |
| Oct 25 | 0 | 45 | 0 | 0 |
| Nov 25 | 0 | 47 | 1 | 0 |
| Dec 25 | 2 | 58 | 0 | 0 |
| Jan 26 | 0 | 34 | 0 | 0 |
| Feb 26 | 1 | 31 | 1 | 0 |
| Mar 26 | 0 | 31 | 1 | 0 |
| Apr 26 | 39 | 81 | 1 | 0 |
| May 26 | 12 | 52 | 0 | 0 |
| Jun 26 | 5 | 49 | 0 | 0 |
| Jul 26 | 0 | 45 | 1 | 0 |
| Aug 26 | 0 | 41 | 0 | 0 |
| Sep 26 | 0 | 40 | 0 | 0 |
| Oct 26 | 0 | 41 | 1 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
4 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2176-2017 · Started Apr 27, 2017
Cause as FDA categorized it: Under Investigation by firm · Device type: Tubes, Gastrointestinal (And Accessories) (KNT)
Z-2177-2017 · Started Apr 27, 2017
Reason given: PEG kits have the potential for one of the following defects: missing components, duplicate components or missing label/Instructions for Use, which includes expiry information.
Cause as FDA categorized it: Under Investigation by firm · Device type: Tubes, Gastrointestinal (And Accessories) (KNT)
Z-2178-2017 · Started Apr 27, 2017
Reason given: PEG kits have the potential for one of the following defects: missing components, duplicate components or missing label/Instructions for Use, which includes expiry information.
Cause as FDA categorized it: Under Investigation by firm · Device type: Tubes, Gastrointestinal (And Accessories) (KNT)
1 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.